Skip to main content
TipRanks
Go Ultimate75% OFF

Biomerica (BMRA) AI Stock Analysis

402 Followers
BMRA

Biomerica

(NASDAQ:BMRA)

Select Model
Rating:42Neutral
Price Target:$1.00â–¼(-19.03% Downside)
Action:reiterated
Date:11/18/26

The score is primarily driven by very weak fundamentals (persistent losses, extremely thin margins, and ongoing cash burn) and bearish technicals (price below key moving averages with negative MACD). A small offset comes from the recent financing that supports near-term liquidity, but valuation remains constrained by loss-making operations and the absence of dividend support.

Positive Factors
Diagnostic Product ModelThe company operates in diagnostic products and consumables, with revenue tied to healthcare testing by laboratories and providers. Consumable testing can support repeat purchasing, while multiple customer channels and product categories provide a foundation for rebuilding scale over time.
Negative Factors
Revenue ContractionMaterial revenue contraction indicates that the company has not yet demonstrated durable demand expansion or a sustained return to scale. Persistently low sales can limit operating leverage, weaken the ability to absorb fixed costs, and make future profitability dependent on a meaningful commercial recovery.

Biomerica (BMRA) vs. SPDR S&P 500 ETF (SPY)

-60%-40%-20%0%20%40%BMRA-44.62%SPY+13.46%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$5.68M
Dividend Yield
―
Average Volume (3M)
72.97K
Price to Earnings (P/E)
-0.8
Beta (1Y)
2.03
Revenue Growth
-11.20%
EPS Growth
-6.64%
Country
US
Employees
50
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Biomerica Business Overview & Revenue Model

Company Description

Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. T...

How the Company Makes Money

Biomerica makes money primarily by selling its diagnostic products and related consumables to customers such as clinical laboratories, hospitals/clinics, and distributors. Revenue is generally generated from (1) product sales of test kits and assays...

Biomerica Financial Statement Overview

Summary

Financial performance is weak: revenue contracted sharply and remains low, gross margin is extremely thin, and the company continues to post deep operating and net losses. Cash flow is consistently negative (operating cash flow and free cash flow), implying ongoing funding needs, while leverage has increased despite still-positive equity.

Income Statement

12Very Negative

Balance Sheet

42Neutral

Cash Flow

18Very Negative
Financial statement breakdown
BreakdownTTMAug 2026May 2025May 2024May 2023May 2022
Income Statement
Total Revenue4.45M4.45M5.31M5.42M5.34M18.87M
Gross Profit360.00K362.00K498.00K611.00K446.00K2.98M
EBITDA-3.73M-4.90M-4.57M-5.56M-6.74M-3.94M
Net Income-3.77M-3.77M-4.97M-5.98M-7.14M-4.53M
Balance Sheet
Total Assets6.76M6.76M5.95M9.25M14.45M11.37M
Cash, Cash Equivalents and Short-Term Investments1.31M1.31M2.40M4.17M9.72M5.92M
Total Debt1.88M2.38M458.00K785.00K1.08M1.38M
Total Liabilities4.13M4.13M1.84M2.66M2.73M3.05M
Stockholders Equity2.63M2.63M4.11M6.59M11.72M8.32M
Cash Flow
Free Cash Flow-3.46M-3.42M-3.88M-5.48M-5.55M-650.87K
Operating Cash Flow-3.42M-3.42M-3.84M-5.36M-5.47M-480.53K
Investing Cash Flow-1,000-1,000-37.00K-115.00K-78.00K-170.34K
Financing Cash Flow2.33M2.33M2.11M-81.00K9.39M2.39M

Biomerica Technical Analysis

Technical Analysis SentimentNegative
Last Price1.24

Price Trends

50DMA1.94Negative
100DMA1.83Negative
200DMA1.99Negative

Market Momentum

MACD-0.16Positive
RSI24.11Positive
STOCH18.94Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BMRA, the sentiment is Negative. The current price of 1.24 is below the 20-day moving average (MA) of 1.59, below the 50-day MA of 1.94, and below the 200-day MA of 1.99, indicating a bearish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 24.11 is Positive, neither overbought nor oversold. The STOCH value of 18.94 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BMRA.

Biomerica Risk Analysis

Biomerica disclosed 33 risk factors in its most recent earnings report. Biomerica reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Nasdaq's recently adopted minimum Market Value of Listed Securities requirement of $5 million could result in the suspension and delisting of our common stock from Nasdaq.Q2, 2026
2.Our revenues have declined, and there is no assurance that we will reverse this trend.Q2, 2026
3.Advances in artificial intelligence and competing diagnostic technologies could reduce demand for our products.Q2, 2026

Biomerica Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

BMRA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
HSCSHSCS45Neutral$10.24M-0.64-816.25%―-27.70%61.44%
SSKNSSKN43Neutral$5890.00-268.41%―-8.54%40.91%
PAVMPAVM42Neutral$12.07M-0.16-58.07%―410.34%-185.92%
BMRABMRA42Neutral$5.68M-0.79-142.81%―-11.20%-6.64%
AMIXAMIX40Underperform$2.21M-0.05-191.88%――81.59%

* Healthcare Sector Average

Performance Comparison

-50%0%50%BMRASSKNPAVMHSCSAMIXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
BMRA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
BMRABiomerica Inc1.24-1.01-44.87%
SSKNStrata Skin Sciences0.09-1.22-93.13%
PAVMPavmed1.51-9.18-85.87%
HSCSHeart Test Laboratories, Inc.2.06-0.85-29.21%
AMIXAutonomix Medical, Inc.1.08-19.87-94.85%

Biomerica Corporate Events

Executive/Board ChangesShareholder Meetings

Biomerica Announces Board and Governance Committee Transition

Neutral
Oct 15, 2026

On October 12, 2026, Biomerica, Inc. disclosed that director David Moatazedi will not stand for re-election at the company’s 2026 Annual Meeting of Stockholders, scheduled for December 11, 2026. Moatazedi, who joined the Board in December 2022, curre...

Private Placements and FinancingRegulatory Filings and Compliance

Biomerica Completes Private Placement of Equity Securities

Positive
Aug 26, 2026

On August 20, 2026, Biomerica entered into a securities purchase agreement with institutional and individual investors, including B. Riley Principal Capital and certain directors and executives, to sell 1,393,705 common shares at $1.60 each, raising...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 18, 2026